Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis1 passage
• Collective impact of conventional cardiovascular risk factors and coronary calcium score on clinical outcomes with or without statin therapy: The St Francis Heart Study1 passage
• Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial1 passage
• Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial1 passage
• Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of care1 passage
• Diastolic hypotension due to intensive blood pressure therapy: Is it harmful?1 passage
• Differential effect of atorvastatin and pravastatin on thoracic spine attenuation: A sub-analysis of a randomized clinical trial1 passage
• Effect of rosuvastatin or its combination with omega-3 fatty acids on circulating CD34(+) progenitor cells and on endothelial colony formation in patients with mixed dyslipidaemia1 passage
• Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database1 passage
• Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial1 passage
• Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study1 passage
• Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial1 passage
• Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial1 passage
• Efficacy and safety of statins, ezetimibe and statins-ezetimibe therapies for children and adolescents with heterozygous familial hypercholesterolaemia: Systematic review, pairwise and network meta-analyses of randomised controlled trials1 passage
• Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score"1 passage
• Is the lower risk of venous thromboembolism with statins related to low-density-lipoprotein reduction? A network meta-analysis and meta-regression of randomised controlled trials1 passage
• Oxidized phospholipid dynamics in the early post-infarction period: Effects of PCSK9 inhibition with evolocumab1 passage
• Serum uric acid concentrations and risk of intracerebral hemorrhage: A systematic review and meta-analysis1 passage
• Soluble endoglin as a biomarker of cardiovascular and metabolic disorders related to endothelial dysfunction: a systematic review and meta-analysis1 passage